Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic virus that causes severe respiratory disease in humans with case fatality rates close to 40%, but for which no vaccines are available. Here, we evaluated the utility of ChAdOx1, a promising replication-deficient simian adeno...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Springer Nature
2017
|
| _version_ | 1797061057681817600 |
|---|---|
| author | Munster, V Wells, D Lambe, T Wright, D Fischer, R Bushmaker, T Saturday, G van Doremalen, N Gilbert, S de Wit, E Warimwe, G |
| author_facet | Munster, V Wells, D Lambe, T Wright, D Fischer, R Bushmaker, T Saturday, G van Doremalen, N Gilbert, S de Wit, E Warimwe, G |
| author_sort | Munster, V |
| collection | OXFORD |
| description | Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic virus that causes severe respiratory disease in humans with case fatality rates close to 40%, but for which no vaccines are available. Here, we evaluated the utility of ChAdOx1, a promising replication-deficient simian adenovirus vaccine vector platform with an established safety profile in humans and dromedary camels, for MERS-CoV vaccine development. Using a transgenic lethal BALB/c MERS-CoV mouse model we showed that single dose intranasal or intramuscular immunization with ChAdOx1 MERS, encoding full-length MERS-CoV Spike glycoprotein, is highly immunogenic and confers protection against lethal viral challenge. Immunogenicity and efficacy were comparable between immunisation routes. Together these data provide support for further evaluation of ChAdOx1 MERS vaccine in humans and dromedary camels, the animal reservoir of infection. |
| first_indexed | 2024-03-06T20:25:39Z |
| format | Journal article |
| id | oxford-uuid:2f4ddc26-9f71-46a2-b192-0bc47c67f1e7 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:25:39Z |
| publishDate | 2017 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:2f4ddc26-9f71-46a2-b192-0bc47c67f1e72022-03-26T12:54:29ZProtective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse modelJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2f4ddc26-9f71-46a2-b192-0bc47c67f1e7Symplectic Elements at OxfordSpringer Nature2017Munster, VWells, DLambe, TWright, DFischer, RBushmaker, TSaturday, Gvan Doremalen, NGilbert, Sde Wit, EWarimwe, GMiddle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic virus that causes severe respiratory disease in humans with case fatality rates close to 40%, but for which no vaccines are available. Here, we evaluated the utility of ChAdOx1, a promising replication-deficient simian adenovirus vaccine vector platform with an established safety profile in humans and dromedary camels, for MERS-CoV vaccine development. Using a transgenic lethal BALB/c MERS-CoV mouse model we showed that single dose intranasal or intramuscular immunization with ChAdOx1 MERS, encoding full-length MERS-CoV Spike glycoprotein, is highly immunogenic and confers protection against lethal viral challenge. Immunogenicity and efficacy were comparable between immunisation routes. Together these data provide support for further evaluation of ChAdOx1 MERS vaccine in humans and dromedary camels, the animal reservoir of infection. |
| spellingShingle | Munster, V Wells, D Lambe, T Wright, D Fischer, R Bushmaker, T Saturday, G van Doremalen, N Gilbert, S de Wit, E Warimwe, G Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model |
| title | Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model |
| title_full | Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model |
| title_fullStr | Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model |
| title_full_unstemmed | Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model |
| title_short | Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model |
| title_sort | protective efficacy of a novel simian adenovirus vaccine against lethal mers cov challenge in a transgenic human dpp4 mouse model |
| work_keys_str_mv | AT munsterv protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT wellsd protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT lambet protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT wrightd protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT fischerr protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT bushmakert protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT saturdayg protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT vandoremalenn protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT gilberts protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT dewite protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel AT warimweg protectiveefficacyofanovelsimianadenovirusvaccineagainstlethalmerscovchallengeinatransgenichumandpp4mousemodel |